You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 18, 2025

Drugs in MeSH Category Neuromuscular Nondepolarizing Agents


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys PANCURONIUM BROMIDE pancuronium bromide INJECTABLE;INJECTION 072760-001 Jul 31, 1990 RX No Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Elkins Sinn PANCURONIUM BROMIDE pancuronium bromide INJECTABLE;INJECTION 072059-001 Mar 23, 1988 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Hikma ATRACURIUM BESYLATE atracurium besylate INJECTABLE;INJECTION 074901-001 Jul 18, 1997 AP RX No Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Hospira VECURONIUM BROMIDE vecuronium bromide INJECTABLE;INJECTION 075164-002 Oct 21, 1999 AP RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Norvium Bioscience ATRACURIUM BESYLATE atracurium besylate INJECTABLE;INJECTION 206096-001 Jun 22, 2017 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Neuromuscular Nondepolarizing Agents Market Analysis and Financial Projection

The market for neuromuscular nondepolarizing agents (NMBAs) is shaped by increasing surgical demand, patent expirations, and innovations in reversal agents. Here's a detailed analysis:

Market Dynamics

  • Growth Drivers:
    The global NMBA market was valued at $1.5 billion in 2022, projected to reach $2.5 billion by 2030 (CAGR: 7.2%)[9][12]. Non-depolarizing agents dominate the market, with a subset (e.g., rocuronium, vecuronium) valued at $1.8 billion in 2024, expected to grow to $2.4 billion by 2031[5]. Key drivers include:

    • Rising surgical volumes (e.g., abdominal, thoracic procedures)[9].
    • Aging populations requiring more interventions[9][12].
    • Advancements in anesthesia and minimally invasive techniques[5][9].
  • Leading Products:

    • Bridion (sugammadex): Merck’s reversal agent for rocuronium/vecuronium-induced blockade generated $487 million in Q1 2023 (+23% YoY)[3]. Its patent protection was extended to January 2026, securing Merck’s market position[3].
    • Vecuronium bromide: A steroidal NMBA with multiple patents (e.g., US 3,553,212) held by Organon USA[4].
  • Regional Trends:
    Emerging markets (Asia-Pacific, Latin America) drive growth through healthcare infrastructure improvements[5][9]. Developed regions focus on novel agents and reversal technologies[12].


Patent Landscape

  • Key Patents and Innovations:

    • Reversal Agents:
    • Sugammadex: Patented cyclodextrin derivative (US 8,592,451B2) binds rocuronium/vecuronium for rapid reversal[6][10].
    • Neostigmine: First generic versions (e.g., Eurohealth’s) gained FDA approval, though associated with risks like postoperative desaturation[8][14].
    • Drug Formulations:
    • US 8,592,451B2: Covers reversible nondepolarizing agents with reduced circulatory side effects[6].
    • US 2005/0192243A1: Focuses on antagonists for ultra-short-acting NMBAs[7].
  • Competitive Strategies:

    • Patent Litigation: Merck’s legal victory extending Bridion’s exclusivity exemplifies tactics to delay generics[3].
    • Non-Product-Specific Patents: Post-approval manufacturing patents (e.g., mRNA technologies) block biosimilars, as seen in biologics[15].

Challenges and Trends

  • Clinical Risks:
    Intermediate-acting agents (e.g., rocuronium) correlate with postoperative desaturation (OR 1.36) and reintubation risks, even with neostigmine reversal[14].

  • Innovation Focus:

    • Targeted Covalent Inhibitors: 2020–23 patents highlight KRAS G12C, BTK, and SARS-CoV-2 Mpro as top targets, though NMBA-specific R&D remains niche[2].
    • Selective Agents: Development prioritizes faster onset, shorter duration, and fewer side effects (e.g., US 2005/0153932A1 for controlled blockade)[10].
  • Market Competition:

    • Generics: Approvals for vecuronium and neostigmine intensify price competition[4][8].
    • Academic Involvement: Institutions like Dana-Farber Cancer Institute lead in covalent drug patents[2].

Key Takeaways

  • The NMBA market is expanding due to surgical demand, with non-depolarizing agents and advanced reversal drugs like Bridion driving growth.
  • Patent strategies (e.g., term extensions, manufacturing patents) are critical for maintaining exclusivity.
  • Clinical challenges (e.g., residual blockade) underscore the need for safer reversal mechanisms.
“The constant depolarization and triggering of the receptors keeps the endplate resistant to activation by acetylcholine.” – Mechanism of depolarizing agents[1].

FAQs

  1. How does sugammadex differ from neostigmine?
    Sugammadex encapsulates NMBAs for direct reversal, while neostigmine increases acetylcholine levels[13][11].

  2. What risks are linked to intermediate-acting NMBAs?
    Higher odds of postoperative oxygen desaturation and reintubation, even with reversal agents[14].

  3. Which companies dominate the NMBA market?
    Merck (Bridion), Organon (vecuronium), and generics manufacturers like Eurohealth[3][4][8].

  4. How do patents impact biosimilar entry?
    Post-approval manufacturing patents create legal barriers, delaying competition[15].

  5. What is the role of cyclodextrins in NMBA reversal?
    They form complexes with steroidal NMBAs (e.g., rocuronium) to rapidly restore muscle function[6][10].

References

  1. https://en.wikipedia.org/wiki/Neuromuscular-blocking_drug
  2. https://pubmed.ncbi.nlm.nih.gov/39219095/
  3. https://www.biospace.com/merck-secures-bridion-patent-protection-through-january-2026
  4. https://www.drugpatentwatch.com/p/generic-api/vecuronium+bromide
  5. https://www.openpr.com/news/3915936/global-non-depolarizing-muscle-relaxants-market-outlook-2025
  6. https://patents.google.com/patent/US8592451B2/en
  7. https://patents.google.com/patent/US20050192243A1/en
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC4745634/
  9. https://www.verifiedmarketreports.com/product/neuromuscular-blocking-agent-nmba-market/
  10. https://patents.google.com/patent/US20050153932A1/en
  11. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203629Orig1s000SumR.pdf
  12. https://www.thebusinessresearchcompany.com/report/neuromuscular-blocking-drug-global-market-report
  13. https://www.merck.com/news/mercks-bridion-sugammadex-receives-fda-approval-for-the-reversal-of-neuromuscular-blockade-induced-by-rocuronium-and-vecuronium-in-adults-undergoing-surgery/
  14. https://www.bmj.com/content/345/bmj.e6329
  15. https://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=4128&context=dlj

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.